STROBE Statement—Checklist of items that should be included in reports of ***cross-sectional studies***

	Item No	Recommendation	Reported on Page Number / Line Number
Title and abstract	1	(*a*) Indicate the study's design with a commonly used term in the title or the abstract	Page 1 Line 1-2
		(*b*) Provide in the abstract an informative and balanced summary of what was done and what was found	Page 3 Line 33-55
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	Page 4-5 Line 60-95
Objectives	3	State specific objectives, including any prespecified hypotheses	Page 5 Line 96-101
Methods			
Study design	4	Present key elements of study design early in the paper	Page 6 Line 111-113
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	Page 6 Line 115-124
Participants	6	(*a*) Give the eligibility criteria, and the sources and methods of selection of participants	Page 6 Line 111-113
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	Page 10-11 Line 154-178
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	Page 7-10 Line 136-152
Bias	9	Describe any efforts to address potential sources of bias	Page 10-11 Line 154-178
Study size	10	Explain how the study size was arrived at	Page 6 Line 111-113
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	Page 10-11 Line 154-178
Statistical methods	12	(*a*) Describe all statistical methods, including those used to control for confounding	Page 11-13 Line 188-226
		(*b*) Describe any methods used to examine subgroups and interactions	Page 11-13 Line 188-236
		(*c*) Explain how missing data were addressed	
		(*d*) If applicable, describe analytical methods taking account of sampling strategy	
		(*e*) Describe any sensitivity analyses	
Results			
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	Page 13-15 Line 229-241
		(b) Give reasons for non-participation at each stage	

		(c) Consider use of a flow diagram	
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	Page 13-15 Line 229-241
		(b) Indicate number of participants with missing data for each variable of interest	
Outcome data	15*	Report numbers of outcome events or summary measures	Page 16-32 Line 228-359
Main results	16	(*a*) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	Page 16-19 Line 252-270
		(*b*) Report category boundaries when continuous variables were categorized	
		(*c*) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	Page 20-32 Line 271-361
Discussion			
Key results	18	Summarise key results with reference to study objectives	Page 33 Line 363-374
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	Page 38 Line 503-514
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	Page 33-38 Line 375-503
Generalisability	21	Discuss the generalisability (external validity) of the study results	Page 38 Line 504-506
Other information			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	Page 41 Line 560-562

*Give information separately for exposed and unexposed groups.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at http://www.plosmedicine.org/, Annals of Internal Medicine at http://www.annals.org/, and Epidemiology at http://www.epidem.com/). Information on the STROBE Initiative is available at www.strobe-statement.org.

Article information: http://dx.doi.org/10.21037/apm-20-2435
*As the checklist was provided upon initial submission, the page number/line number reported may be changed due to copyediting and may not be referable in the published version.